Feedback / Questions
rosnilimab (ANB030) - AnaptysBio
Rosnilimab: "69% (220/318) achieved LDA at week 14 (NRI)"; Rheumatoid arthritis
(44th Annual J.P. Morgan Healthcare Conference, AnaptysBio)
Jan 14, 2026
P2b data
•
Rheumatoid Arthritis
https://jpmorgan.metameetings.net/events/healthcare26/sessions/317556-anaptysbio-inc/webcast?gpu_only=true&kiosk=true
Jan 14, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious